RinuaGene

About RinuaGene

RinuaGene, officially Renjing (Suzhou) Biotechnology Co., Ltd., is a biotechnology firm founded in 2021 by Dr. Yijie Dong, who previously worked at Bristol-Myers Squibb Co.. The company is headquartered in Suzhou, China, and focuses on developing messenger RNA (mRNA) based therapeutics and vaccines to address unmet medical needs, particularly in oncology and infectious diseases. The core team comprises professionals with experience from multinational pharmaceutical companies like Merck, Novartis, Johnson & Johnson, and AstraZeneca.

The company has built an end-to-end platform for RNA drug research, development, and production. This platform integrates four core technologies: linear mRNA, circular RNA, a proprietary Lipid Nanoparticle (LNP) targeted delivery system, and Chemistry, Manufacturing, and Controls (CMC). RinuaGene also utilizes AI and data science in its development process. As of late 2024, the company had filed over 90 patent applications to protect its product pipeline and technology platforms.

A key product in RinuaGene's pipeline is RG002, a therapeutic mRNA vaccine for treating infections and lesions caused by high-risk human papillomavirus (HPV) types 16 and 18. In late 2023, RG002 received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), followed by IND approval from China's National Medical Products Administration (NMPA) in late 2024, marking it as the first mRNA product globally to receive clinical approval for this indication. The company initiated the Phase I clinical trial for RG002 in April 2025. Other pipeline products include prophylactic vaccines for infectious diseases, with several in the IND application stage. The company's business model centers on generating revenue through the development and commercialization of these innovative drugs.

RinuaGene has secured significant funding to advance its research and clinical trials. It completed a seed round in February 2023 for $14.7 million and a Series A round in April 2026, raising CNY 200 million (approximately $29.1 million). Investors include Qingdao Caitong Group, Chang'an Capital, and K2VC. These funds are allocated towards advancing the clinical development of its core products and the commercialization of its research.